CVE:SVA

Sernova Stock Forecast, Price & News

C$1.57

+0.09 (+6.08%)

(As of 06/1/2022)

Add

Compare

Today's Range: C$1.46
▼
C$1.57
50-Day Range: C$1.38
▼
C$1.57
52-Week Range: C$1.16
▼
C$2.22

Volume: 121,355 shs
Average Volume: 288,358 shs
Market Capitalization: C$432.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter.

SVA Stock Forecast (MarketRank)

Overall MarketRank^™

1.19 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Sernova.

4.3 Community Rank

Outperform Votes
Sernova has received 43 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sernova has received 25 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Sernova has received 63.24% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sernova and other stocks. Vote “Outperform” if you believe SVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sernova does not currently pay a dividend.
Dividend Growth
Sernova does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sernova insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$64,500.00 in company stock and sold C$0.00 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sernova has a P/B Ratio of 15.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sernova (CVE:SVA)

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

June 22, 2022 | americanbankingnews.com

Sernova Corp. (CVE:SVA) Director Frank Holler Purchases 50,000 Shares of Stock

June 15, 2022 | globenewswire.com

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June - GlobeNewswire

June 15, 2022 | finance.yahoo.com

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June

June 10, 2022 | ca.finance.yahoo.com

Sernova Corp. (SVA.TO)

June 6, 2022 | globenewswire.com

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022 - GlobeNewswire

June 2, 2022 | finance.yahoo.com

Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development - Yahoo Finance

June 2, 2022 | finance.yahoo.com

Altos Labs Announces Sponsored Research Agreement with Kyoto University's CiRA to Foster Cellular Rejuvenation Programming Research - Yahoo Finance

June 2, 2022 | finance.yahoo.com

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference - Yahoo Finance

May 17, 2022 | globenewswire.com

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes - GlobeNewswire

May 17, 2022 | finance.yahoo.com

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes - Yahoo Finance

May 17, 2022 | finance.yahoo.com

Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes - Yahoo Finance

March 24, 2022 | businesswire.com

2022 Global Conformal Coatings Technology Growth Opportunities - ResearchAndMarkets.com - Business Wire

January 10, 2022 | ca.finance.yahoo.com

IIROC Trading Halt - SVA

See More Headlines

Industry, Sector and Symbol

Stock Exchange: CVE
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: CVE:SVA
CUSIP: N/A
CIK: N/A
Web: www.sernova.com
Phone: +1-519-8585184
Fax: N/A
Employees: 1,959
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1.34
Current Ratio: 13.76
Quick Ratio: 13.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.10 per share
Price / Cash Flow: 15.10
Book Value: C$0.10 per share
Price / Book: 15.10

Miscellaneous

Outstanding Shares: 275,525,000
Free Float: N/A
Market Cap: C$432.57 million
Optionable: Optionable
Beta: N/A

Sernova Frequently Asked Questions

Should I buy or sell Sernova stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sernova stock.
View analyst ratings for Sernova or view top-rated stocks.
How has Sernova's stock price performed in 2022?: Sernova's stock was trading at C$1.82 at the beginning of 2022. Since then, SVA shares have decreased by 13.7% and is now trading at C$1.57.
View the best growth stocks for 2022 here.
Who are some of Sernova's key competitors?: Some companies that are related to Sernova include MaxCyte (MXCT), Profound Medical (PRN), Renalytix (RENX), Profound Medical (PRN), Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), GENinCode (GENI) and genedrive (GDR).
View all of SVA's competitors.
What other stocks do shareholders of Sernova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sernova investors own include Gilead Sciences (GILD), New Residential Investment (NRZ), SMART Global (SGH), Big Lots (BIG), Bernstein U.S. Research Fund (BERN), Bank of America (BAC), Alibaba Group (BABA), AstraZeneca (AZN), Liberty All-Star Growth Fund (ASG) and Ares Capital (ARCC).

What is Sernova's stock symbol?: Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."
How do I buy shares of Sernova?: Shares of SVA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Sernova's stock price today?: One share of SVA stock can currently be purchased for approximately C$1.57.
How much money does Sernova make?: Sernova (CVE:SVA) has a market capitalization of C$432.57 million.
How many employees does Sernova have?: Sernova employs 1,959 workers across the globe.
How can I contact Sernova?: Sernova's mailing address is 700 Collip Cir Suite 114, LONDON, ON N6G 4X8, Canada. The official website for Sernova is www.sernova.com. The company can be reached via phone at +1-519-8585184.

This page (CVE:SVA) was last updated on 6/29/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources